2011’s Top Biopharma Dealmakers
Executive Summary
Big Pharma entered into fewer in-licensing deals in 2011 than it did in 2010. Top M&As focused on emerging markets. And neurology, cancer and metabolic disease were the most lucrative therapeutic areas in alliances.